Loading patent…
AssigneeSun Pharma Advanced Research Company Ltd.
InventorsAjay Jaysingh Khopade, Arindam Halder
Estimating the term…
The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.
A method of treating glaucoma in a patient need thereof comprising administering to the patient an ophthalmic formulation comprising an aqueous suspension containing brimonidine or its pharmaceutically acceptable salt at a concentration of from about 0.05 to about 0.5% weight by volume, and a cation exchange resin, wherein the suspension is suitable for once-a-day topical instillation.
A method of treating glaucoma in a patient need thereof comprising administering to the patient an ophthalmic formulation comprising brimonidine or a pharmaceutically acceptable salt thereof at a concentration of about weight by volume, a cation exchange resin, and a suspending agent, wherein the ophthalmic formulation is an aqueous suspension and is suitable for once-a-day topical instillation.
A method of treating glaucoma in a patient need thereof comprising administering to the patient an ophthalmic formulation comprising (a) reversible clusters of drug loaded ion-exchange resin particles, said clusters having a D50 value of at least 2 micrometers and (b) a suspending agent, wherein the ophthalmic formulation is an aqueous suspension and the drug is brimonidine or its pharmaceutically acceptable salt at a concentration of from about 0.05% to about 0.5% weight by volume.
Dependencies are inferred from the claim text.